---
layout: default
title: Inclisiran
parent: Model Prediction Only (L5)
nav_order: 401
evidence_level: L5
indication_count: 10
---

# Inclisiran
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Inclisiran: From Hypercholesterolemia (LDL-C Lowering) to Potassium Deficiency Disease

## One-Sentence Summary

Inclisiran is a PCSK9-targeted siRNA therapeutic whose established pharmacology lowers LDL cholesterol by silencing PCSK9 expression. The TxGNN model's top-ranked prediction points to **Potassium Deficiency Disease**, but this evidence pack itself flags the association as a likely knowledge-graph embedding artifact — **0 clinical trials** and **0 publications** support it, and no plausible mechanistic pathway connects PCSK9 inhibition to potassium/electrolyte metabolism.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack (DrugBank query returned no `original_indications`; drug not marketed in Canada) |
| Predicted New Indication | Potassium Deficiency Disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Canada Market Status | ✗ Not marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Inclisiran is currently unavailable (flagged as a High-severity data gap, DG002). Based on information embedded in the evidence pack's own repurposing rationale, Inclisiran acts through the **PCSK9/LDLR pathway** as an siRNA agent that lowers LDL-C — a mechanism with no known physiological overlap with potassium or electrolyte homeostasis.

The evidence pack's own mechanistic assessment for this candidate states directly: *"電解質代謝疾病與 PCSK9 抑制無已知生理路徑重疊，機轉連結不存在，屬圖譜嵌入偽關聯"* (electrolyte metabolic disease shares no known physiological pathway with PCSK9 inhibition; the mechanistic link does not exist and this is judged a knowledge-graph embedding artifact). This is a candid, model-generated caveat rather than an independent clinical hypothesis, and it should be weighted heavily against this specific prediction.

By contrast, several lower-ranked candidates in this same pack (e.g., migraine disorder, rank 4; Raynaud disease, rank 10) at least carry an indirect, literature-adjacent hypothesis linking PCSK9 inhibition to vascular endothelial function — still speculative, but mechanistically more coherent than the top-ranked result reported here.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Potassium Deficiency Disease) is explicitly characterized within the evidence pack itself as a likely graph-embedding false positive with no known mechanistic pathway. Across 31 systematic queries (ClinicalTrials.gov, ICTRP, PubMed) spanning all 10 predicted indications for this drug, zero trials and zero publications were found. The drug is also not marketed in Canada, and TFDA/label safety data (warnings, contraindications) remain a Blocking data gap (DG001), preventing any S1 safety assessment.

**To proceed, the following is needed:**
- TFDA/Health Canada product label — warnings, contraindications (DG001, blocking)
- Confirmed mechanism-of-action documentation from DrugBank or primary literature (DG002)
- Original indication data for Inclisiran (currently absent from this evidence pack)
- If pursuing repurposing further, re-prioritize toward mechanistically plausible candidates (e.g., migraine disorder, Raynaud disease) rather than this top-ranked but graph-artifact-flagged prediction
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

